Global Assets Advisory’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Global Assets Advisory’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,000	Closed	-$104K	–	338
2026 Q1	$104K	Buy	+2,000	New	+$81.9K	0.03%	296

Other funds holding BBC

KCP

Kera Capital Partners San Jose, California $1.04B AUM 52.56% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

MCM

Militia Capital Management Austin, Texas $3.37B AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Global Assets Advisory's BBC Position: Q2 2026 in Review

Global Assets Advisory sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q2 2026, closing a stake of 2,000 shares — an estimated $104K sold.

Global Assets Advisory first reported a position in BBC in Q1 2026 and held it in 1 quarter. The position peaked at $104K in Q1 2026. 20 funds tracked by Wall St. Rank hold BBC as of Q2 2026.

Global Assets Advisory reported no remaining Virtus Biotech Clinical Trials ETF position as of Q2 2026 after selling out during the quarter.
Global Assets Advisory sold 2,000 Virtus Biotech Clinical Trials ETF shares in Q2 2026, an estimated $104K.
Global Assets Advisory first reported a position in Virtus Biotech Clinical Trials ETF in Q1 2026 and held it in 1 quarter.
Global Assets Advisory's Virtus Biotech Clinical Trials ETF position peaked at $104K in Q1 2026.
20 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q2 2026.

Based on Global Assets Advisory's 13F filing for Q2 2026, filed 27 Jul 2026.